1. Scrip
  2. >>Business

Agomab Gets $100m In Fifth Largest European Venture Round This Year

 
• By Elizabeth Cairns

But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.

cash investment

AgomAb Therapeutics NV’s first nine-figure venture round is the fifth largest this year for a Europe-based company, and ought to see the company through Phase II development of its lead compound, a therapy for fibrostenosing Crohn’s disease.

Key Takeaways
  • Agomab’s cash injection will get its lead compound through its first Phase II trial, and two other programs through Phase I
  • The company will need partners to address what could be an enormous market
  • Pfizer and Boehringer Ingelheim

But the trial, which has only just started, is not powered to show AGMB-129’s effects on hard endpoints like signs and symptoms, so Agomab’s backers will have to wait some time to find out whether their investment is likely to come good

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.